Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. (Q33418378)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Olivier Huillard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Michel Vidal

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Marie-Anne Loriot

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

A Cessot

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

A Thomas-Schoemann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J L Golmard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

P Boudou-Rouquette

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

A Behouche

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

F Taieb

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J P Durand

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

A Dauphin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

R Coriat

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M Tod

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J Alexandre

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

F Goldwasser

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

B Blanchet

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

25 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

257-268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344452%20AND%20SRC:MED&resulttype=core&format=json

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Targeted therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Influence of lean body weight on anticancer drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Relationships between body composition parameters and fluorouracil pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Quantification of lean bodyweight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Lean body mass as a predictor of drug dosage. Implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

Regulation of vascular tone during pregnancy: a novel role for the pregnane X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0178-2

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.

21 January 2018

1 reference

12 December 2020

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib

1 reference

12 December 2020

CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients

1 reference

12 December 2020

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

1 reference

12 December 2020

Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate

1 reference

12 December 2020

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662

1 reference

12 December 2020